Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Dose Comparison in Platinum-Resistant Ovarian Cancer
NCT04787289Phase 2Recruiting
- Sponsor
- BC Cancer
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bevacizumab in ovarian cancer, sponsored by BC Cancer. Primary endpoint: Progression-Free Survival at 4 years. Started Sep 2021; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04787289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787289.